Yuval Shaked

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.